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Background: Cervical dystonia is characterized by involuntary muscle contractions of the neck and abnormal head
positions that affect daily life activities and social life of patients. Patients are usually treated with botulinum toxin
injections into affected neck muscles to relief pain and improve control of head postures. In addition, many
patients are referred for physical therapy to improve their ability to perform activities of daily living. A recent review
on allied health interventions in cervical dystonia showed a lack of randomized controlled intervention studies
regarding the effectiveness of physical therapy interventions.
Methods/design: The (cost-) effectiveness of a standardized physical therapy program compared to regular
physical therapy, both as add-on treatment to botulinum toxin injections will be determined in a multi-centre,
single blinded randomized controlled trial with 100 cervical dystonia patients. Primary outcomes are disability in
daily functioning assessed with the disability subscale of the Toronto Western Spasmodic Torticollis Rating Scale.
Secondary outcomes are pain, severity of dystonia, active range of motion of the head, quality of life, anxiety and
depression. Data will be collected at baseline, after six months and one year by an independent blind assessor just
prior to botulinum toxin injections. For the cost effectiveness, an additional economic evaluation will be performed
with the costs per quality adjusted life-year as primary outcome parameter.
Discussion: Our study will provide new evidence regarding the (cost-) effectiveness of a standardized, tailored
physical therapy program for patients with cervical dystonia. It is widely felt that allied health interventions,
including physical therapy, may offer a valuable supplement to the current therapeutic options. A positive outcome
will lead to a greater use of the standardized physical therapy program. For the Dutch situation a positive outcome
implies that the standardized physical therapy program forms the basis for a national treatment guideline for
cervical dystonia.
Trial registration: Number Dutch Trial registration (Nederlands Trial Register): NTR3437
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Cervical Dystonia (CD), or torticollis, is a disabling
neurological disorder characterized by abnormal posi-
tions of the head due to involuntary muscle contractions
of the neck [1]. The posture in CD patients can feature
one or a combination of postures: rotation (torticollis);
lateral tilting (laterocollis); flexion (anterocollis); exten-
sion (retrocollis); and lateral shift. With an estimated
prevalence of 5.7 patients per 100.000 persons in
Western Europe, CD is the most common form of pri-
mary adult onset dystonia which usually starts after the
age of 30 [2]. Pain is experienced in two-thirds to three-
quarters of patients and is a major source of disability,
which is strongly associated with the presence of muscle
contractions and head deviations [3-6]. Decreased self-
efficacy, fatigue, anxiety and depression are other factors
associated with disability in cervical dystonia [7]. Re-
search on focal dystonia’s, including CD, revealed abnor-
malities in basal ganglia function, cerebellar function,
sensory processing, motor inhibition, neuro-plasticity
and somatotopic cortical organisation but the patho-
physiology remains largely unclear [8]. Treatment op-
tions for CD are mainly symptomatic, aiming to reduce
involuntary movements, correct abnormal head posi-
tions and reduce pain. Currently, the best evidence
based treatment option is to inject the dystonic neck
muscles with botulinum toxin (BTX) [9-12]. The effects
of BTX fluctuate over time. A peak effect occurs within
2–4 weeks after injections and is followed by a decrease
of effect and return of symptoms. On average new injec-
tions are given within 12–14 weeks after the previous in-
jections (Figure 1) [13].
In addition to BTX treatment, many CD patients in
the Netherlands are referred for physical therapy (PT).
However, due to the rarity of CD, experience among
Dutch PT’s is lacking. Besides, the evidence for the
effects of PT on the ability to perform activities of daily
living in CD is very limited. [14] Only two small Random-
ized Controlled Trials (RCT) and one open controlled3 months 6 months
Baseline 1st measurem





Figure 1 Effect of BTX and expected additional effect of PT. Effect of B
CD, pain and disability to perform daily life tasks. Red lines illustrate the no
effect of the PT program.study investigated the effects of a PT program on CD
[15-17]. All studies compared BTX treatment in combin-
ation with a PT program versus BTX treatment alone. All
studies showed significant better scores on pain and dis-
ability in the groups receiving BTX treatment with an add-
itional PT program. The PT programs in all three studies
consisted of intense motor learning exercises (postural
control, balance, strengthening axial musculature and fa-
cilitation of voluntary movement), and mobilization tech-
niques of the cervical spine and dystonic muscles. PT
programs varied from 40 minutes per session every other
day for six weeks [16], 75 minutes per session 5 days a
week for five weeks [17] up to 90 minutes a day for 2
weeks [15]. Although the results of these PT treatments
were positive, it is difficult to implement them to current
regular care of chronic diseases provided by physiothera-
pists and exercise therapists. For most patients and thera-
pists it will not be feasible to combine such an intensive
program with their daily lives and practice.
One approach towards the treatment of CD was sug-
gested by the French physiotherapist J.P. Bleton [18].
The main goals of this program are the rehabilitation of
the antagonist muscles and the control of the dystonic
movements by frequent training in a functional context.
Exercises are taught during one or two PT sessions a
week. After teaching the patients, intensive training is
required in the patient’s environment (up to 10 times a
day for 10 minutes). In addition, patients are encouraged
to correct the dystonic posture during their daily live ac-
tivities by turning their head in the opposite direction of
the dystonic posture. Eventually, patients should be able
to control the dystonic movements independently. This
approach with increasing control of the patients and de-
creasing therapist involvement seems more applicable
than the intensive programs by Tassoreli, El Bahwrady
and Queiroz [15-17]. The effect of the Bleton treatment
has never been investigated in a large randomized con-
trolled trial. Not only for practical reasons, but also
based on the pathophysiological knowledge of CD, a9 months 12 months
ent Final measurement
am
TX. Increasing lines indicate a better effect of BTX and less severity of
rmal effect of BTX, blue dotted lines illustrate the expected additional
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proach and independent continuation of the treatment
program seems more appropriate for the long term ben-
efits of PT [15].
In the current study we developed a PT program with
elements of the approach suggested by Bleton. We
added current knowledge of motor (re) learning prin-
ciples, coaching and principles of providing feedback in
a standardized PT treatment program (Table 1). This
resulted in a standardized, tailored PT program com-
prising of a one year training that aims to improve the
ability to perform daily life tasks by emphasizing inde-
pendent training in the patient’s own environment
[18-20]. The standardized PT treatment program was
developed according the AGREE standards [21] in cor-
poration with the Royal Dutch Society for Physiotherapy
(KNGF), the Society for Cesar- and Mensendieck Exer-
cise Therapy (VvOCM) and the Amsterdam School of
Health Professions (ASHP). The standardized PT pro-
gram was developed within the DystonieNet, a national
collaboration between neurologists and allied health pro-
fessionals in research, education and treatment of CD,
which was initiated by the neurology departments of
four university hospitals in the Netherlands [22]. The
standardized PT program aims to relearn or adopt alter-
native/new movement strategies to improve activities in
daily life situations.
The primary objective of this study is to evaluate the
effectiveness of the standardized PT program on im-
proving the ability to perform daily life activities in CD
patients compared to usual PT that is given in Dutch
private practices. Both PT programs are add-on treat-
ment to BTX-injections. Measurement will take place
just prior to the BTX injections as it is hypothesized that
the effects of the PT program will mainly occur in the
period between the injections when the BTX wears off
and symptoms return (Figure 1). Secondary objectives
are to evaluate the effects on severity of CD pain, quality
of life, anxiety and depression.
In addition, cost effectiveness will be detremined by
comparing the costs and health utility of the new stan-
dardized PT program with the care as usual PT treat-
ment. It is hypothesized that the standardized PT
program will be more cost effective and more effective
in improving the ability to perform daily life tasks of CD
patients than regular PT.
A positive outcome of this study will lead to the devel-
opment of a national treatment guideline which will be
implemented via the Dutch DystonieNet.
Methods/design
Study design
The study will be conducted as a multi-center single
blind randomized controlled trial in three Dutch universityhospitals. Patients will be randomly assigned to the
experimental group or control group using a computer-
ized randomization protocol. Patients in the expe-
rimental group will be referred to specialized PT’s who
are trained prior to the study to perform the standard-
ized PT program. Patients in the control group will be
referred to regular PT’s and receive care as usual. All
data will be collected at baseline, after six months and
after one year. In order to determine the additional
effects of a PT program, measurements will be per-
formed briefly before the BTX injections at the out-
patient clinics of the hospitals. This implies that we
measure the effect of the PT program in a period that
BTX has the least effect on the symptoms of dystonia
(Figure 1). Measurements will be performed by a blind
and independent assessor since it is impossible to blind
the therapists and patients for treatment allocation.
Participants
The study aims to include 100 patients with primary CD
of 30 years and older, stable on BTX treatment for more
than one year. Exclusion criteria are secondary or her-
editary forms of dystonia, dystonia in other bodyparts
than the neck and patients who had surgery for the
treatment of dystonia.
Interventions
Standardized, tailored PT program
Subjects in this group receive a one year PT program
according the standardized PT program in combination
with BTX injections. The PT program will start two
weeks after the injections. The emphasis of the PT pro-
gram is on the functional performance of the exercises
adapted to daily life situations, muscle stretching, passive
mobilization of the neck and training principles which
have found to be relevant for neural rehabilitation and
motor learning and will be performed by trained phys-
ical therapists [18-20]. A summary of the theoretical
basis with respect to ‘muscle stretching and mobilizations’ ,
‘motor (re)learning’, ‘transference and generalization’, ‘feed-
back’ and ‘self management’, is displayed in Table 1.
Regular PT
Subjects randomized in this group will receive BTX in-
jections and regular PT once a week for a period of one
year. In contrast to the standardized PT program, inter-
ventions are not given by specialized therapists. Due to
the rarity of CD, the average therapist in the Netherlands
has little knowledge about CD. It is likely that common
interventions like massage, stretching and exercise of the
dystonic muscles are used. Specific information of the
weekly sessions and treatment will be retrieved from the
local PT’s after the patients finished the study period of
one year.
Table 1 Theoretical background of the standardized PT program
Muscle stretching /relaxation and mobilisations (de Morree [43], Fung [44])




Passive mobilization techniques of the neck create stress relaxation in
the collagen fibers of the cervical facet joints. This helps to increase
ROM




Stretching elongates the dystonic muscle and helps to relax it due to
the Golgi tendon reflex.
Passive stretching of dystonic muscles
Motor learning principles (Kleim & Jones [20])
Principle Explanation Application in standardized PT program
1. Use it or lose
it
Failure to drive specific brain functions can lead to functional
degradation.
Activation of antagonists
2. Use it and
improve it
Training that drives a specific brain function can lead to an
enhancement of that function.
Training of antagonists in order to improve voluntary
movement of the head
3. Specificity The nature of the training experience dictates the nature of the
plasticity.








Induction of plasticity requires sufficient training intensity. Training intensity is tailored for the individual and
monitored over time
6. Time matters Different forms of plasticity occur at different times during training. 1 year of therapy is divided in 3 stages according the 3
stages model of Fitts & Postner [45]
7. Salience
matters
The training experience must be sufficiently salient to induce
plasticity.
Functional training of activities of daily living tailored to
the individual needs of the patient
8. Age matters Training-induced plasticity occurs more readily in younger brains.
9. Transference Plasticity in response to one training experience can enhance the
acquisition of similar behaviors.
Functional training of activities of daily living tailored to
the patients needs and variation and random practice
10. Interference Plasticity in response to one experience can interfere with the
acquisition of other behaviors.
Transference and generalization (Shea & Morgan [45], Schmidt & Lee [46])
Principle Explanation Application in standardized PT program
1. Random
practice
Enhances the transference and generalization of a task Tasks or exercises are given in a random order
2. Variation of
practice
Enhances the transference and generalization of a task Specific tasks or exercises are performed in different
contexts
Feedback (Shea et al. [47], Schmidt & Lee [46])




Feedback is essential for learning to take place. Summary KR is that
KR is given after an entire set of trials during an exercise instead of
after each individual trial. It is the most effective form for the
retention and transference of a task.
Feedback is given after each set of trials of a task. Each
task is performed at least 5 times after feedback is
provided
Self management (Fitts & Posner three-stage model [48])
Principle Explanation Application in standardized PT program
1. Cognitive
phase
The learner is concerned with understanding a task and developing
strategies to perform a task and how the task can be evaluated.
These efforts require a high degree of cognitive activity
During the first month patients receive 2 PT sessions a
week to (re)learn and understand movement strategies.
Movement strategies will be practiced at home 5–10 times
a day for 10–15 minutes
2. Associative
phase
The learner has selected the best strategy for a task and starts to
refine it. This stage requires less cognitive activity
During this stage patients receive 1 PT session. Movement
strategies from the first stage will be increased in difficulty.
Movement strategies will be practiced at home 5–10 times
day for 10–15 minutes
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Table 1 Theoretical background of the standardized PT program (Continued)
3. Autonomous
phase
The learner is able to perform a skill automatically. A low degree of
attention is required.
During the last (autonomous) stage, patients are
encouraged to perform the learned tasks independently
and to improve and maintain their (re)gained abilities
themselves. Therapists will have a coaching role. Patients
receive one PT session a month for additional advice and
motivation.
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Disability
Disability as measured with the disability subscale of the
Toronto Western Spasmodic Torticollis Rating Scale
(TWSTRS) is the primary outcome of this study. The
TWSTRS scale is a widely used scale in research and is a
valid and reliable tool to measure severity, disability and
pain in CD (Kendall Tau = 0.85, p < 0.01) [23,24]. The
disability section is a six point Likert scale which con-
sists of six items like driving a car, reading and
performing ADL activities (max 30 points). Lower scores
indicate less disability.
Disability will also be measured with the Functional
Disability Questionnaire (FDQ). The FDQ is a 27 item
scale to measures the impact of CD on daily functioning.
Questions are asked about the extent to which CD af-
fects the engagement in and performance of a sample of
activities at the present time. Each item is rated on a 5-
point scale (maximal score 68 points) The FDQ has a
high reliability (r=.93, P<0.001) [25].
Severity of CD
Severity of CD will be measured with the Tsui scale [26].
The Tsui scale measures different aspects of abnormal
posture and movements in CD patients. It has a max-
imal score of 25 points. The Tsui-scale is a widely used,
standardized and reliable scale (ICC=.86) to measure the
severity of CD [26] Lower scores indicate less severity of
dystonia.
Severity of CD will also be measured with the Clinical
Global Impressions-Severity of Illness Scale (CGI-S) and
the Clinical Global Impression - Improvement scale
(CGI-I). Both scales are observer- or patient- rated scale
that measure illness severity and global improvement on
a 7-point scale. Both scales are widely used and reliable
and validated for a numerous of disorders (r=0.41 to
0.77, p=0,05 for self perceived measures and r=0.36 to
0.84, p=0.05 of clinician administered measures of anx-
iety, depression, impairment and quality of life) [27,28].
Active range of motion
To determine the changes in the ability to perform vol-
untary movements, active range of motion (AROM) will
be measured with a cervical range of motion meter
(CROM) [29]. The CROM is a frame that will be placed
on the head with three separate inclinometers tomeasure AROM in the sagittal, coronal and horizontal
planes. First the resting position of the head will be mea-
sured and subsequently the AROM of flexion, extension,
lateral flexion and rotation. Although the psychometric
properties of the CROM in patients with CD are un-
known, in a healthy population the CROM is a reliable
instrument to measure cervical ROM (intratester reli-
ability ranged .63-.93 intertester reliability ranged .74 -
.87) [29]. To determine the additional effects of PT on
pain, patient are asked to rate their pain on a Numeric
Rating Scale (NRS). A score of 0 means no pain and a
score of 10 means the worst pain imaginable. The NRS
is a validated and reliable tool for the assessment of pain
(Spearman r =.94 between VAS and NRS, test-retest reli-
ability ICC = .90) [30,31].
Quality of life
Quality of Life (QoL) will be measured with the Cranio-
cervical Dystonia Questionnaire (CDQ-24) and Short
Form 36 (SF-36) [32,33]. The CDQ-24 is a validated and
disease specific, self reporting questionnaire to evaluate
quality of life of patients with cervical dystonia on a five
point likert scale [32]. The CDQ-24 subscales showed
moderate to high correlations with those SF-36 subscales
measuring similar aspects (Pearson’s correlation r =
0.50–0.73; P<0.001, each).The score ranges from 0 to 96
points where lower scores indicate a better QoL. The
SF-36 is a validated generic measure for QoL containing
36 items measuring eight dimensions of health [33].
Scores of the different dimensions can range from 0
(worst) to 100 (best).
Anxiety and depression
Since 25 to 59% of the CD patients suffer from anxiety
disorders or depression [25,34], the effects of PT are de-
termined with the Beck’s Anxiety Index [35] and Beck’s
Depression Index [36,37]. Both instruments are validated
and reliable tools and are rated on a 21 item 4 point
Likert scale (BDI: r = .73 with Hamilton Psychiatric Rat-
ing Scale for Depression. BAI: test-retest reliability coef-
ficient of .67, R=.54, p=0.05 with anxiety).
Cost effectiveness
To determine the cost effectiveness of both physical
therapy programs, the costs per quality adjusted life year
(QALY) will be calculated. In addition, cost-effectiveness
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the costs per unit on the TWSTRS-disability scale as the
outcome measure. Costs which are associated with loss
of productivity due to disability or inability to work will
be registered in the subgroup of patients below the age
of 65 with the Productivity Costs Questionnaire (PCQ)
and EuroQoL-5D (EQ-5D). The PCQ is a 22 item
generic questionnaire used to measure absence of work
due to health problems and is advised as standard in-
strument for use in economic evaluations of Dutch
healthcare [38,39]. The EQ-5D is a six item, standard-
ized measure of health status in order to provide a sim-
ple, generic measure of health for clinical and economic
appraisal [39,40].
Sample size
The power calculation is based on the study by Brans
et al. investigating the long term effect of BTX on dis-
ability and functional health [41]. This study showed an
average improvement of 7.1 out of 30 points on the dis-
ability subscale of the TWSTRS after 1 year of BTX
treatment in CD patients. It is estimated that the add-
itional effect of the PT program according the treatment
guideline will be at least half the effect caused by BTX.
The cut off for the success of the PT program is there-
fore, set on an average improvement of 3.5 out of 30
points on the TWSTRS disability scale which is clinically
relevant according Brans et al. [42]. With a power of
0.80 and an alpha of 0.05, each group will need 44 sub-
jects. With a loss of 10% taken into account, 50 subjects
in each group are required.
Analysis
Differences in all outcome measures, with exception of
the measures for cost effectiveness, will be determined
with a mixed between-within (repeated measures) ana-
lysis of variance for both treatment arms, across three
time periods (baseline, after six months and one year).
All analyses will be performed under the intention to
treat principle in SPSS 20.0. Differences will be consid-
ered significant at p-value < 0.05.
The cost effectiveness will be determined by a cost-
utility analysis from a societal perspective with a time
horizon of one year. Cost-utility analysis facilitates the
comparative assessment of health care innovations ac-
ross different types of interventions, disease areas and
health care settings. Incremental cost-utility and cost-
effectiveness ratios for the add-on standardized PT pro-
gram versus add-on regular PT will be calculated as the
extra costs per QALY gained and the extra costs per unit
decrease in TWSTRS-disability score. The cost effective-
ness will be calculated according the most recent guide-
lines for unit costing in healthcare research [40]. The
friction cost method will be applied to calculate thecosts of production loss as measured with the PCQ, EQ-
5D. Unit costs of production loss will be based on the
most recent national guidelines for unit costing in
healthcare research [40]. The base year for unit costing
will be 2013.
Ethical considerations
In accordance with the local medical ethics committee
(MEC) guidelines, written informed consent is required
from participants who fulfil the selection criteria. The
study has been approved by the Medical Ethics Commit-
tee of the Academic Medical Center, Amsterdam (MEC
2012_048). This study is registered under Trial registra-
tion number NTR3437 of the Dutch trial registration
(Nederlands Trial Register).
Discussion
In our study we aim to fill the gap in evidence based
medicine to treat CD patients with PT by performing a
large RCT towards the (cost) effectiveness of a standard-
ized, tailored PT program. There are several differences
of this study compared to studies reported in the current
available literature.
Although other studies have showed added value of
short, high intensity PT program on pain and disability
in combination with BTX treatment, follow-up measure-
ments were not performed and therefore it is not known
if a wash out of treatment effects will occur [15-17].
Since CD is a life lasting disorder, a longer treatment
period seems more appropriate to establish lasting
changes. We therefore choose for a treatment period of
one year in contrary to the other studies which lasted
five weeks maximal [15-17]. Another difference with
other studies is that the standardized PT program tends
to teach patients themselves, how to improve their abil-
ity to perform daily life tasks and to manage their symp-
toms in their own environment. To establish lasting
changes and the ability of patients to manage their
symptoms in their own environment, we have chosen
for a treatment period of one year. The standardized
treatment program itself is based on modern principles
about motor learning, transference and generalization of
learned tasks to enhance lasting (neuroplastic) changes
(Table 1) [20,43-48]. Based on these principles, we aimed
for a tailored, evidence based intervention that is
thought to be more effective than regular interventions.
It is hypothesized that the overall added effect of the
standardized PT program on the BTX treatment lies be-
tween the periods that the BTX is starting to wear off
and the BTX is starting to work again after new injec-
tions (Figure 1). Other studies performed measurements
in the periods when the peak effect of BTX occurred (2–
4 weeks after injections) which make it impossible to de-
termine the additional effects of a PT program on CD
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PT just prior to the BTX injections when the interfer-
ence of BTX effects are minimal.
Another goal of the standardized treatment program is
to make patients less dependent of healthcare providers
and to decrease the healthcare costs for this patient
group.
In the Netherlands many CD patients are referred for
physical therapy. Since CD is a chronic indication for
PT, patients receive (except for the first 20 treatments)
unlimited reimbursement for PT which results in long
lasting use of healthcare in the current, regular situation.
We therefore added an economic evaluation to compare
the cost effectiveness of the standardized PT program
with physical therapy care as usual.
Future implications
In the case of a positive outcome of this study, the stan-
dardized PT program will be used as a basis for a na-
tional treatment guideline which will be implemented
via the Dutch DystonieNet.
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